03-25-2014, 10:12 AM
(This post was last modified: 03-25-2014, 10:15 AM by Dividend Watcher.)
Well, my re-balance is just about done.
Here's my latest portfolio makeup:
I trimmed some HRS & WAG. I actually sold a little more WAG than I wanted to but, with the yield down around 2%, it was easy to add to the dividend stream at a higher yield. Don't plan on selling any more since I feel they've got a good growth plan for the next few years as long as they keep the dividend growth rate up there.
As mentioned before, added to DE a little at a decent price. Also added to UL on the dip and opened a position in OHI.
I still have the April covered call on INTC but it's back out of the money at this moment. If its exersized, I'm OK with that. If not, I'll sell another CC.
Still have an open cash-secured put on MAT but it keeps climbing. It's not a conviction stock but the yield still looks good and willing to wait out management fixing the sales stream. We'll see what happens.
My big worry is the cc on ABBV (I mentioned that in the Options thread). It's bouncing around in and out of the money without any seeming news to move it far in any direction. Their HEP C drug has finished phase III trials but I think anything definitive won't come out about production until after the put expires. Long term, ABBV is a company I like and their pipeline is pretty broad but still in the early stages. Their looking at another possible treatment for Humira. If so, that could extend the patent protection for Humira on that indication and protect some of that revenue stream.
As for the rest, I'm satisfied where I'm at for now. Still want to add some O and OHI and open some positions in AVA and CLX. Was hoping Yellen taking over the Fed and interest rates to give me some movement but it looks like the Mr. Market is happy to keep inching up.
In my wife's portfolio, this is where we're at:
As mentioned, I sold VOD with the uncertainty around the VZ deal and trimmed WAG once again (and that's it!).
Took the proceeds and added to TU and added to HCP. Sitting on a limit order for JNJ in the mid-80s which should give us a yield above 3% but might have to wait on that unless we have a decent correction. In the meantime, if PG corrects or one of the others on her watch list takes a tumble, I'll cancel the JNJ order and purchase something else.
Next up for her would be a triple-net REIT (favoring WPC or NNN right now) or a ute -- possibly WEC or SO. Still looking at adding to KRFT but would prefer it closer to 50 than 55 so that might replace the JNJ order also.
As we both keep aging and so far none of the drug majors have come out with a forever young pill
, I'm slowly transitioning to higher yielding companies. A recession or good correction should help with that.
Thoughts?
Here's my latest portfolio makeup:
I trimmed some HRS & WAG. I actually sold a little more WAG than I wanted to but, with the yield down around 2%, it was easy to add to the dividend stream at a higher yield. Don't plan on selling any more since I feel they've got a good growth plan for the next few years as long as they keep the dividend growth rate up there.
As mentioned before, added to DE a little at a decent price. Also added to UL on the dip and opened a position in OHI.
I still have the April covered call on INTC but it's back out of the money at this moment. If its exersized, I'm OK with that. If not, I'll sell another CC.
Still have an open cash-secured put on MAT but it keeps climbing. It's not a conviction stock but the yield still looks good and willing to wait out management fixing the sales stream. We'll see what happens.
My big worry is the cc on ABBV (I mentioned that in the Options thread). It's bouncing around in and out of the money without any seeming news to move it far in any direction. Their HEP C drug has finished phase III trials but I think anything definitive won't come out about production until after the put expires. Long term, ABBV is a company I like and their pipeline is pretty broad but still in the early stages. Their looking at another possible treatment for Humira. If so, that could extend the patent protection for Humira on that indication and protect some of that revenue stream.
As for the rest, I'm satisfied where I'm at for now. Still want to add some O and OHI and open some positions in AVA and CLX. Was hoping Yellen taking over the Fed and interest rates to give me some movement but it looks like the Mr. Market is happy to keep inching up.
In my wife's portfolio, this is where we're at:
As mentioned, I sold VOD with the uncertainty around the VZ deal and trimmed WAG once again (and that's it!).
Took the proceeds and added to TU and added to HCP. Sitting on a limit order for JNJ in the mid-80s which should give us a yield above 3% but might have to wait on that unless we have a decent correction. In the meantime, if PG corrects or one of the others on her watch list takes a tumble, I'll cancel the JNJ order and purchase something else.
Next up for her would be a triple-net REIT (favoring WPC or NNN right now) or a ute -- possibly WEC or SO. Still looking at adding to KRFT but would prefer it closer to 50 than 55 so that might replace the JNJ order also.
As we both keep aging and so far none of the drug majors have come out with a forever young pill
, I'm slowly transitioning to higher yielding companies. A recession or good correction should help with that.Thoughts?
=====
“While the dividend itself is merely a rearrangement of equity, over time it's more like owning an apple tree. The tree grows the apples back again and again and again, and the theoretical value of the tree doesn't change just because of when the apples are about to fall.” - earthtodan
“While the dividend itself is merely a rearrangement of equity, over time it's more like owning an apple tree. The tree grows the apples back again and again and again, and the theoretical value of the tree doesn't change just because of when the apples are about to fall.” - earthtodan